Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
- Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity
SCLC is an aggressive disease with limited treatment options. Approximately 30,000 patients in
“As a leader in allogeneic CAR T research and development, we are committed to exploring the potential of this therapeutic modality across a broad range of indications, including in solid tumors where there is significant need," said
This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates. The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity. The results from the pre-clinical study showed:
- No DLL3 on target toxicity was observed in preclinical models supporting a potentially attractive safety profile
- Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in mice without normal tissue toxicity
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to further research and develop ALLO-213 or any other anti-DLL3 AlloCAR T candidate; and the potential benefits of any anti-DLL3 AlloCAR T candidate or any other AlloCAR T candidate. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 8-K filed on
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene’s AlloCAR T™ programs utilize Cellectis technologies. The anti-DLL3 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.
Allogene Media/Investor Contact:
Chief Communications Officer
1Lung cancer - small cell - statistics. Cancer.Net. (2023,
Source: Allogene Therapeutics, Inc.